Bioxytran Inc (QB) (BIXT) 뉴스

There be whale sized bids this week on $BIXT

That's a good read. Looking for a good entry point, any suggestion?

https://www.insiderfinancial.com/post/galectin-therapeutics-nasdaq-galt-disrupting-mercks-cancer-dominance

Just out today and BIXT is in there

I think that's a good level if there's any kind of squeeze.  Look at the filings.  Insiders converted commons into preferreds. Why? 

Uhh, is that good?

Only 35 mil shares in the unrestricted float 

https://www.otcmarkets.com/stock/BIXT/security

BIXT.  Filings and more! 

https://www.linkedin.com/pulse/keytruda-neutralized-galectin-3-over-60-patients-michael-sheikh-mcowc

Hard to read from the app but looks like insiders are disposing shares?  Is there a link to the 8k? 

SEC 8-K and Form 4 filed this morning. BIXT bought the other company and owns both patents now, and the assets were appraised at 2 times the current Market cap. And I am loving it.

ED-Jmer can troll all he wants to.

Only a fool believes this

LOL, could be. Find out when they go to Buy To Cover!!!

BIXTmentioned in this article

https://www.zerohedge.com/news/2024-10-15/what-merck-doesnt-want-you-know-about-keytruda

Only 35 mil shares in the float

https://www.otcmarkets.com/stock/BIXT/security

This guy works for bixt according to otcmarkets.


Mike Sheikh, BS, is a US Air Force Academy graduate and pilot. He has a Bachelor's of Science in Economics and flew KC-135 tankers and worked as a budget officer in the comptroller's squadron. He has prior experience as a broker and research analyst. After the brokerage industry, he was a business development officer for a variety of specialty finance companies. He is a long-time Biotech Consultant expert for public or private biotech companies with disruptive technologies. Mr. Sheikh the founder of Falcon Strategic Research, which focuses on companies that are not covered by traditional analysts on Wall Street. He is also the founder of an Investor Relations Firm.

Very good news Ecomike. Thanks

That doesn’t prove there are shorts or naked shorts. I’m asking you to back up your statement with something factual besides the cost to borrow.

100% Correct

Are those Korean Hedge Funds still short a Trillion shares?

Then why is the cost to borrow up something crazy like 4000% above normal? It is even higher than Game stop was when it bankrupted a hedge fund with a 6.4 Billion dollar loose. Note worthy that the cost to borrow exploded when 1/2 the OS common shares were cancelled.

Except that the FDA has already issued a Phase III IND approval for the Long Haul Covid19 trials and India just as close on the Phase III trial approval for the Covid 19 trial.

BIXT has already proven their product works on Shingles as a skin cream. And they scored 10 Million dollars of grant money from the Heme Foundation.

And Humans are refusing to take clot shot vaccines anymore.

With FED interest rates in full reversal, Biotech funding, that the US FED killed 2 years ago, when the FED jacked up FED Interest rates and choked off the money supply that nearly broke the US Banking system, is starting to come back.

I don’t believe there is a single share that’s been shorted naked or otherwise

There’s no evidence so there’s no truth to the statement

Yes, all those are important issues. However, one issue is tantamount and that would be the FDA who protects their assets and friends. Under normal conditions ...normal in the past.... this would already be hitching a ride on an Elon Mars venture.

It never occurred to me that this naked short drama might eventually culminate in a discovery process that helps the Securities and Exchange Commission expose the shorts' tactics and--hopefully--hamstring their efforts to suppress the PPS and f*ck retail out of hard earned money...THANKS!

Hard to tell with the Hedge fund naked shorts in Asia and the UK that never report (New SEC rule says they must now, but they are fighting that in court, which is awesome as enables the discover process the SEC wants to nail them with.

The cost to borrow is crazy high, like Game Stop was when retail wiped a 64 Billion dollar hedge fund.

How many shares are short??

There are dozens of documents and 100s and hundreds of pages of documents, slide shows and info on the Bioxytran website, enough to get lost in for weeks

The shorts have almost no shares left to borrow, this the huge, and the cost to borrow is higher than Game Stop was in 2021 when the hedge fund went broke and lost 6.4 Billion dollars shorting game stop. Retail won and proved retail can win. Hollywood made a movie about it, and named it "Dumb Money" LOL

Also what about a pointer and draw some circles and lines around things that your explaining to make you point really clear and to show that you definitely believe in what you’re saying and then make them to some real investors

Not bad the video maybe he should get rid of the probably thought

Please watch this and comment your opinion !

There has to be a pump first

Don’t get left holding the EGOmike pump bag again

The cost to borrow rate on $BIXT is past the level that triggered the Game stop rally that bankrupted a hedge fun with a 6.4 Billion dollar loss.
This is assuming that the shorts have to borrow shares... it applies for retail traders but doesn't affect the big hedge funds that naked short with impunity.

The cost to borrow rate on $BIXT is past the level that triggered the Game stop rally that bankrupted a hedge fun with a 6.4 Billion dollar loss.

Borrowing rate to short BIXT went up. Was 7.41 and is now 7.74 late this week. Shorts underestimated $BIXT. as 0.25 is a normal borrowing rate. Shorts miss-calculated big time, here is why:

Short video of key parts of the long video. If you are follower of #galectinscience then this talk about #Cancer #metastasis is one that you CANNOT miss. Dive into #galectins & how their potential as a universal target in #Oncology.

https://t.co/0W0x1ksWq6

Universal, plasma-blood safe, for all blood types, Oxygen Carrier that can bypass blood clots and boost oxygen levels to limit organ and brain damage from accidents, and blood clots.

Universal, Patented, Nontoxic Carb Based Antiviral.

https://finance.yahoo.com/news/bioxytrans-medical-breakthrough-fighting-viruses-133500730.html

Universal Cancer Killer via Galectin Antagonists? (The solution to stopping metastasis of cancer cells which is what really kills people?)

Cancelled a Million dollar loan/share S-1 deal. (Guess they no longer need money) That is huge.

Scored a 10 Million dollar grant for the HEME_Foundation to complete the oxygen carrier molecule for blood plasma use.
Blood plasma by itself can not carry any oxygen. With the BIXT Oxygen carrier added it will be able to carry oxygen, even past blood clots.

Cancelled 50% of the entire OS shares, (Not retail) held by insiders.



Anyone else noticing a pattern here?

Ask and thy shall receive. May take us several re-runs watching it to get it all.

How did the conference go

Any insight

$BIXT live free conference interview and update 11:30 EST today

Use this link:

https://goto.webcasts.com/starthere.jsp?ei=1677125&tp_key=64e020ccee&sti=icon

https://x.com/search?q=%24BIXT&src=typed_query&f=live

https://www.bioxytraninc.com/press-releases

Well put...The possibilities for Bioxytran are indeed staggering, potentially. The issue with startups--as ever--is funding, exposure, and timing. It looks like we're off to a good start with financing. As long as the company is well run and well connected at some point it seems like it's only a matter of time--and perhaps a little luck--before we see a meaningful ROI with this one...GLTUA!!!

Peer reviewed

https://finance.yahoo.com/news/bioxytrans-medical-breakthrough-fighting-viruses-133500730.html/

I'm intrigued by the potential here, but this is definitely one where you buy some shares with money you can afford to lose, set them aside, and see where this ends up in a few years. Or just follow the story and invest later if successful, but at a higher price with less risk.

I suppose that the new was presented and taken as a joke; so humorously 🤡

I don’t think it was insiders. Look at the filings. They converted commons into preferreds and reduced OS by 70mil shares or roughly 1/2.

I bought a few this week and continue to hold a large bag.

Not calling this an out right buy. I found the PR encouraging but lack of movement on that news is troubling me.

If it’s all bs. The bag will get larger. If they are now looking for a partner to invest to bring this thru trials we could easily see .50 All speculation on my part I’m loosing a ton here.

So is the company or the shorts selling since the selling seems sizable enough on a Friday after massive news so who would be selling on life changing news or was that just some bull?

wash rinse repeat

lower highs followed by lower lows

click the price chart/graph over on the right side --try 1 year

Looks like pump followed by the dump

If Bioxytrans has patients on such a Glorious claim all Majors must be taken notice: So possibly buyout or takeover would definitely be involved; if not total conniving Suppression Imo

If Bioxytrans has patients on such a Glorious claim all Majors must be taken notice: So possibly buyout or takeover would definitely be involved; if not total conniving Suppression Imo

Interesting the insiders retired commons and exchanged for preferreds just a month ago

What happens next?

$BIXT Major news

https://finance.yahoo.com/news/bioxytrans-medical-breakthrough-fighting-viruses-133500730.html

Bioxytran's Medical Breakthrough in Fighting All Viruses
BioXyTran, Inc.
Thu, September 19, 2024 at 8:35 AM CDT 6 min read
In This Article:
BIXT
+28.37%

Breakthrough was validated in the latest journal article

Galectins are essential for viral entry and a new target for drug development

Carbohydrates were shown to neutralize viruses

Blocking galectins could be the most efficient way to prevent and treat viruses potentially impacting the vaccination and antiviral markets

BOSTON, MA / ACCESSWIRE / September 19, 2024 / BIOXYTRAN, INC. (OTCQB:BIXT) (the "Company"), a clinical stage biotechnology company developing drugs to treat stroke and Alzheimer's disease, announced a medical breakthrough in virology that was validated in a peer-reviewed medical journal article. The European Society of Medicine published a peer-reviewed article detailing a study which shows how Bioxytran's leading drug candidate, Prolectin-M, stops COVID-19 and other viruses in their tracks. The study used advanced Nuclear Magnetic Resonance (NMR) spectroscopy to reveal how this drug works by blocking a protein called galectin, which helps viruses attach to cells. The discovery could impact both the vaccination and antiviral markets, which combined are estimated at approximately $147 billion according to Grandview Research and Statista.

https://esmed.org/MRA/mra/article/view/5616

The peer-reviewed article identified Galectin-3 as a crucial "glue" that helps the virus attach to and enter human cells by sticking to the ACE2 receptor, altering our existing understanding of how viral infections occur. The discovery was proven using NMR Spectroscopy which is extremely precise compared to the 50-year-old ELISA tests which was used to establish virology's initial foundation on how viruses worked and interacted with antivirals. The report proved that by blocking this process, the drugs prevented the virus from entering the cells, which means the virus couldn't make people sick. The double-blind placebo controlled clinical studies showed that these drugs were 100% effective in reducing symptoms and eliminating the virus in 2 peer-reviewed clinical trials.

The study also pointed out that galectins, located on the spike protein of the virus, are an excellent target for drugs because it doesn't change much, making it easier to stop the virus from attaching to cells. This could make these drugs effective against a wide range of viruses, not just COVID-19.

"This discovery might be one of the most significant advancements in virology," said Dr. David Platt, CEO of Bioxytran. "In our first case study to make a SARS-CoV-2 antiviral drug, it appears we have on our hands the first truly broad-spectrum antiviral that may operate across different families of viruses. We believe we have discovered a reproducible method that could potentially be used to create many antiviral drugs that could potentially quickly fight off new viruses, even those that mutate rapidly. We believe our approach represents a new era in antiviral drug development. With the help of advanced technology and Artificial Intelligence (AI), it is now possible to design antiviral drugs that could potentially neutralize any virus. This discovery could change the way we treat viral diseases and even chronic illnesses like cancer. We believe major advancements in virology with this new tech will be measured in months instead of years and decades as has been the case in the past."

"Using this new platform technology could revolutionize how we create new antiviral treatments," said Dr. Kevin Mayo, Professor of the University of Minnesota.

"Traditional methods of developing antivirals and vaccines are not precise and involve a lot of trial and error. Their weakness has always been their reliance on the immune system to work properly and everyone's immune system is unique.

Our results show we can neutralize viruses without the help of the immunes system making our system incredibly reliable. This breakthrough opens a new chapter in fighting viral diseases, providing hope for treating not only SARS-CoV-2 but other highly pathogenic and contagious viruses influenced by galectins. This may be the crown jewel of virology and a few more tests on other viruses could prove it."

Antiviral and Vaccination Market

The global antiviral drugs market is valued at $72.84 billion according to Grandview Research. The global vaccine market is valued at $74.12 billion in 2024 by Statista. Combined the markets total approximately $147 billion. The growth drivers in antivirals are the increasing prevalence of viral infections like HIV, hepatitis, and influenza, along with the increase in antiviral drug development and treatments. The market is dominated by drugs for HIV, hepatitis C, and influenza, with HIV antivirals holding a substantial market share due to the ongoing need for effective treatments. Additionally, there is a growing demand for broad-spectrum antiviral drugs that can be rapidly deployed in response to emerging viral threats.

The COVID-19 pandemic accelerated vaccine development and distribution. New technological advancements in mRNA technology, protein-based vaccines, and microarray patches are enhancing efficacy, stability and accessibility of vaccines. Growing indications include HPV, pneumococcal infections, and RSV. Global health initiatives to combat malaria and tuberculosis are also driving the development of new vaccines.

About Bioxytran, Inc.

Bioxytran, Inc. is a clinical stage biotechnology company pioneering a library of novel complex carbohydrate structures using artificial intelligence software that interprets the Nuclear Magnetic Resonance imaging of druggable targets like the galectin fold to create a rational drug design. The leading drug candidates vetted by in vitro testing, are capable of neutralizing viruses. The peer-reviewed discovery of the galectin fold located on the spike proteins of viruses such as COVID-19, RSV, and H1N1 demonstrate there exists a conserved region on the spike in which Bioxytran's molecules achieve virus neutralization. The extent of the carbohydrate structure's ability to neutralize untested viruses is unknown just like the initial discovery of antibiotics last century and its ability to treat a broad spectrum of bacterial infections. Applications of this platform technology extend to the treatment of significant unmet medical needs in virology, degenerative disease, and hypoxia. The leading drug candidate, Prolectin-M, is a new class of antiviral drug designed to antagonize galectins implicated in inflammatory, fibrotic, and malignant diseases. Bioxytran's other development programs are for pulmonary fibrosis and stroke treatment. More information can be found at www.bioxytraninc.com

Investor Relations
Michael Sheikh
509-991-0245
mike.sheikh@bioxytraninc.com

Forward-Looking Statements

This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release. These forward-looking statements are generally identified by the words "believe," "expect," "anticipate," "estimate," "intend," "plan," and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran's actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward-looking statements and risk factors in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and those risk factors set forth from time-to-time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.

SOURCE: BioXyTran, Inc.



View the original press release

see on accesswire.com

https://www.accesswire.com/920259/bioxytrans-medical-breakthrough-in-fighting-all-viruses